Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Letter to the Editor
  • Published:

Glycogen phosphorylase BB could be a new biomarker for detection of cardiac toxicity during hematopoietic cell transplantation for hematological malignancies

Bone Marrow Transplantation volume 45, pages 1123–1124 (2010)Cite this article

Cardiac toxicity is a well-known and potentially serious complication of hemato-oncology treatment. A preparative regimen (PR) followed by hematopoietic cell transplantation (HCT) represents a high risk for development of cardiotoxicity.1, 2 Various methods including cardiac biomarkers have been recommended for monitoring cardiotoxicity. The applicability of cardiac troponins in this context has been extensively investigated, with inconsistent results.3, 4 Recently, we applied new biomarkers of myocardial ischemia and necrosis—glycogen phosphorylase BB (GPBB) and heart-type fatty acid-binding protein (H-FABP)—in the assessment of cardiac toxicity associated with HCT and anthracycline chemotherapy in acute leukemia patients.5, 6 Except for the acute leukemia setting, these new prospective biomarkers of cardiac injury (GPBB, H-FABP) have not been studied in patients treated for hematological malignancies.

The aim of our present study was to assess cardiac toxicity during PR and HCT for various hematological malignancies using multiple biomarkers of cardiac injury—myoglobin, creatine kinase MB (CK-MB mass), cardiac troponin I (cTnI), H-FABP and GPBB.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Tichelli A, Bhatia S, Socie G . Cardiac and cardiovascular consequences after haematopoietic stem cell transplantation. Br J Haematol 2008; 142: 11–26.

    Article  PubMed  Google Scholar 

  2. Morandi P, Ruffini PA, Benvenuto GM, Raimondi R, Fosser V . Cardiac toxicity of high-dose chemotherapy. Bone Marrow Transplant 2005; 35: 323–334.

    Article  CAS  PubMed  Google Scholar 

  3. Gertz MA . Troponin in hematologic oncology. Leuk Lymphoma 2008; 49: 194–203.

    Article  CAS  PubMed  Google Scholar 

  4. Sparano JA, Brown DL, Wolff AC . Predicting cancer therapy-induced cardiotoxicity. The role of troponins and other markers. Drug Saf 2002; 25: 301–311.

    Article  CAS  PubMed  Google Scholar 

  5. Horacek JM, Tichy M, Pudil R, Jebavy L, Zak P, Ulrychova M et al. Multimarker approach to evaluation of cardiac toxicity during preparative regimen and hematopoietic cell transplantation. Neoplasma 2008; 55: 532–537.

    CAS  PubMed  Google Scholar 

  6. Horacek JM, Tichy M, Pudil R, Jebavy L . Glycogen phosphorylase BB could be a new circulating biomarker for detection of anthracycline cardiotoxicity [letter]. Ann Oncol 2008; 19: 1656–1657.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

This study was supported by research projects MO 0FVZ 0000503 (Czech Ministry of Defence) and MZO 00179906 (Czech Ministry of Health).

Author information

Authors and Affiliations

  1. Department of Medicine 2—Clinical Hematology, University Hospital and Charles University, Faculty of Medicine, Hradec Kralove, Czech Republic

    J M Horacek, L Jebavy, P Zak & J Maly

  2. Department of Internal Medicine, University of Defence, Faculty of Military Health Sciences, Hradec Kralove, Czech Republic

    J M Horacek & L Jebavy

  3. Institute of Clinical Biochemistry and Diagnostics, University Hospital and Charles University, Faculty of Medicine, Hradec Kralove, Czech Republic

    M Ulrychova & M Tichy

  4. Department of Medicine 1, University Hospital and Charles University, Faculty of Medicine, Hradec Kralove, Czech Republic

    R Pudil

Authors
  1. J M Horacek
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. L Jebavy
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M Ulrychova
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M Tichy
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. R Pudil
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. P Zak
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. J Maly
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to J M Horacek.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Horacek, J., Jebavy, L., Ulrychova, M. et al. Glycogen phosphorylase BB could be a new biomarker for detection of cardiac toxicity during hematopoietic cell transplantation for hematological malignancies. Bone Marrow Transplant 45, 1123–1124 (2010). https://doi.org/10.1038/bmt.2009.306

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2009.306

Search

Advanced search

Quick links